Parkinson's Disease study: Trans-Resveratrol
Official title RESvEraTrol in Parkinson's Disease (RESET)
ClinicalTrials.gov ID: NCT07592767
What this study is testing
What is Trans-Resveratrol?
This is an investigational oral medicine being studied as a potential treatment for Parkinson's Disease. It is designed to help the body clean out damaged energy-producing parts of cells and lower inflammation.
Also referred to as Jotrol, JNS115.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study checks if the medicine is safe and how the body handles it. It also looks at how well the body absorbs the drug.
- Who it's for
- People who have been diagnosed with Parkinson's disease.
- What's involved
- Participants take one pill by mouth every day for three months. Some get the real medicine, while others get a sugar pill that looks the same.
- Time commitment
- The study lasts three months and requires regular visits to the clinic.
- Phase 2: a mid-size study of how well it works
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 55 to 85
You may be able to join if
- Capable of providing informed consent (IC) and complying with study procedures
- Stable on Levodopa and/or DA agonists for at least 4 weeks before enrollment
- Clinical diagnosis of PD according to UK Brain Bank criteria and/or PD with Dementia (PDD) by MDS criteria (53-55).
- MoCA≥18.
- Hohn and Yahr stage 2 and 3
You likely can't join if
- Known PD-linked gene mutations e.g. PINK-1, DJ-1, parkin, LRRK2 etc.
- Clinical signs indicating syndromes or disorders other than PD including, Alzheimer's Disease (AD), corticobasal degeneration (CBD), supranuclear...
- Any psychiatric diagnosis or symptoms, (e.g., hallucinations and suicidality, major depression, or delusions) that could interfere with study...
- Medical history of liver or pancreatic disease, GI, ulcers and Chron's disease, kidney, or blood problems.
- Enrolled as an active participant in another clinical study
- Anti-coagulant medications, including Coumadin, heparin, enoxaparin, fondaparinux etc.
See the full eligibility criteria
- Capable of providing informed consent (IC) and complying with study procedures
- Stable on Levodopa and/or DA agonists for at least 4 weeks before enrollment
- Clinical diagnosis of PD according to UK Brain Bank criteria and/or PD with Dementia (PDD) by MDS criteria (53-55).
- MoCA≥18.
- Hohn and Yahr stage 2 and 3
- Age of 55-85 years, medically stable
- English Fluency
- Known PD-linked gene mutations e.g. PINK-1, DJ-1, parkin, LRRK2 etc.
- Clinical signs indicating syndromes or disorders other than PD including, Alzheimer's Disease (AD), corticobasal degeneration (CBD), supranuclear gaze palsy, multiple system atrophy (MSA), chronic traumatic...
- Any psychiatric diagnosis or symptoms, (e.g., hallucinations and suicidality, major depression, or delusions) that could interfere with study procedures
- Medical history of liver or pancreatic disease, GI, ulcers and Chron's disease, kidney, or blood problems.
- Enrolled as an active participant in another clinical study
- Anti-coagulant medications, including Coumadin, heparin, enoxaparin, fondaparinux etc.
- Any immunological disease which is not adequately controlled, or which requires treatment with immunoglobulins, systemic monoclonal antibodies (or derivatives of monoclonal antibodies), systemic immunosuppressant's, or...
- Geriatric Depression Scale (GDS) score greater than or equal to 8 at Screening.
- Answer "yes" to C-SSRS suicidal ideation Type 4 or 5, or any suicidal behavior assessment within 6 months before Screening, at Screening, or at the Baseline Visit, or has been hospitalized or treated for suicidal...
- Planned surgery which requires general anesthesia that would take place during the study.
- Severe visual or hearing impairment that would prevent the subject from performing psychometric tests accurately.
- Women of Childbearing Potential (WCBP) or lactating.
- Must not be on any nutritional or medicinal supplements at least 6 weeks prior to enrollment.
The study team makes the final eligibility decision.
Where it is enrolling
- Washington D.C., District of Columbia, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 55 years to 85 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Washington D.C., District of Columbia, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.